Order Article Reprints

Marcé S, Xicoy B, García O, Cabezón M, Estrada N, Vélez P, Boqué C, Sagüés M, Angona A, Teruel-Montoya R, et al. Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine. 2021; 10(14):3146. https://doi.org/10.3390/jcm10143146

Marcé, Sílvia, Blanca Xicoy, Olga García, Marta Cabezón, Natalia Estrada, Patricia Vélez, Concepción Boqué, Miguel Sagüés, Anna Angona, Raúl Teruel-Montoya, and et al. 2021. "Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib" Journal of Clinical Medicine 10, no. 14: 3146. https://doi.org/10.3390/jcm10143146

Marcé, S., Xicoy, B., García, O., Cabezón, M., Estrada, N., Vélez, P., Boqué, C., Sagüés, M., Angona, A., Teruel-Montoya, R., Ferrer-Marín, F., Amat, P., Hernández-Boluda, J. C., Ibarra, M. M., Anguita, E., Cortés, M., Fernández-Ruiz, A., Fontanals, S., Zamora, L., & on behalf of the Grupo Español de Leucemia Mieloide Crónica (GELMC). (2021). Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. Journal of Clinical Medicine, 10(14), 3146. https://doi.org/10.3390/jcm10143146